Side-by-side · Research reference
P21vsTesofensine
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED8/36 cited
BPhase 3AUTO-DRAFTED10/40 cited
P21
CNTF-Derived Neuropeptide · Animal Model Evidence
Animal onlyEvidence level
SQ · Site unspecified · Frequency unknown
Tesofensine
SNDRI · Phase 3 obesity candidate
Oral · Once daily morning
01Mechanism of Action
Parameter
P21
Tesofensine
Primary target
CNTF receptor alpha (CNTFRα) / LIF receptor (LIFR) / gp130 complex on neural stem cells
Serotonin / norepinephrine / dopamine transporters (SERT / NET / DAT)Astrup 2008
Pathway
CNTF mimetic → CNTFRα/LIFR/gp130 heterotrimer → JAK/STAT3 signaling → neurogenesis, stem cell proliferation, neuroprotection
Triple monoamine reuptake inhibition → ↑synaptic 5-HT, NE, DA → appetite suppression + thermogenesisAstrup 2008
Downstream effect
Increased neural stem cell self-renewal, globose basal cell activation (Mash1+ cells), olfactory sensory neuron regeneration, hippocampal neurogenesis, neuroprotection in developmental disorders
Strong appetite suppression, mild thermogenic effect, weight lossAstrup 2008
Feedback intact?
—
—
Origin
Small-molecule peptide mimetic derived from full-length ciliary neurotrophic factor (CNTF), designed to retain receptor activation with improved pharmacokineticsMottolese 2024
Small molecule developed by NeuroSearch (Denmark) for CNS indications, repurposed for obesityAstrup 2008
Antibody development
—
—
02Dosage Protocols
Parameter
P21
Tesofensine
Human dosing
No established protocol
No clinical trial data available.
—
Animal models (mice)
Dose and route not specified in abstractsMottolese 2024Jia 2020
In vitro and in vivo studies demonstrate efficacy; precise dosing protocols not disclosed.
—
Evidence basis
Animal models only
CDKL5 KO mice, methimazole-induced olfactory injury, CNTF-/- knockout models.Mottolese 2024Cox 2026Jia 2020
Phase 2b + ongoing Phase 3Astrup 2008
Duration
Not specified
24 weeks per studied cycle
Route
Presumed subcutaneous or intraperitoneal (animal studies)
—
Frequency
—
Once daily, morning
Lower / starter dose
—
0.125 mg / day
Form
—
Oral capsule
Timing
—
Morning to avoid sleep disruption
Half-life
—
~9 days (very long)
04Side Effects & Safety
Parameter
P21
Tesofensine
Human safety data
None available
No clinical trials in humans.
—
Animal tolerability
Well-tolerated in mouse models; no toxicity reported in available abstracts
—
Theoretical risks
Uncontrolled stem cell proliferation, immune response to peptide, unknown long-term CNS effects
—
Insomnia
—
Dose-related; mitigate with morning timing
Dry mouth
—
Common
Nausea
—
Common
Mood changes
—
Anxiety / agitation possible
Cardiovascular events
—
Phase 3 trial monitoring; not yet FDA-cleared
Pregnancy / OB
—
Contraindicated
Absolute Contraindications
P21
- ·Use in humans not validated
Tesofensine
- ·Pregnancy / breastfeeding
- ·Severe cardiovascular disease
- ·Concurrent MAOI use
Relative Contraindications
P21
- ·Active malignancy (theoretical — neurotrophic signaling may affect tumour growth)
- ·Pregnancy or lactation (no safety data)
Tesofensine
- ·Hypertension
- ·Anxiety disorder
- ·Insomnia
05Administration Protocol
Parameter
P21
Tesofensine
1. Human protocol
Not established. No FDA approval, no clinical trial data.
Oral capsule (investigational; not commercial).
2. Animal research context
In vivo studies used systemic administration (route not specified in abstracts) in mouse models of neurodegeneration, olfactory injury, and CDKL5 deficiency disorder. In vitro studies used primary cell cultures.
Swallow whole with water, morning only.
3. Timing
—
Morning to mitigate insomnia. Do not dose evening.
4. Storage
—
Room temp ≤25 °C, dry place.
5. Caveat
—
Monitor BP + HR + mood. Avoid stimulants + MAOIs.